Algorithm for #resmetirom treatment from the Global Consensus Recommendations for MASLD and MASH. https://t.co/O3OqWGNvhB

Meta-analysis of anti-diabetic agents in MASH: SGLT2 inhibitors and incretin therapies (tirzepatide, semaglutide, survodutide) significantly improve liver fibrosis in MASH, mainly thanks to weight loss. Dual and triple incretin agonists are top performers for MASH resolution.

Family Law issues? Protect your rights — starting today. Secure a confidential consultation with one of our New Jersey Family Law Attorneys to help safeguard your rights, children, assets, and future.

A large retrospective analysis found that GLP-1 receptor agonist use was not associated with increased risk of aspiration pneumonia, respiratory failure, mechanical ventilation, or hospitalization following screening colonoscopy. https://t.co/P2Khdk9unl

Statins protect against cirrhosis in patients with chronic metabolic liver injury, and the benefit is dose- and age-dependent. https://t.co/H7fFRsXctb

In Swedish MASLD patients, advanced fibrosis was linked to higher hospitalizations and costs. Importantly, noninvasive FIB-4 performed similarly to biopsy in predicting high healthcare utilization. https://t.co/DyDKzBU66a

A brain "dial" for consumption: New research pinpoints the bed nucleus of the stria-terminalis #BNST as an important hub-transforming sweet, salty, and food cues into consummatory responses based on internal state. Manipulating BNST activity can suppress intake (obesity) or boost

Did you know some patients are buying raw GLP‑1 ingredients from China and mixing their own injections to save money on obesity medications? This gray market approach is dangerous. Products can be contaminated, counterfeit, or improperly dosed, leading to infection, severe side

JAMA Cardiol: In >759k US outpatients with HF, <1 in 6 received SGLT2i after approval. Use rose from 4.6% (2019) ➝ 16.2% (2023) but varied widely across practices, with older age, women, and non-diabetes pts less likely to receive therapy. https://t.co/o0gPJETjQI

Algorithm for incidental pituitary adenomas: ▪ Start with dedicated pituitary MRI ▪ Check pituitary labs + visual fields ▪ F/U depends on tumor size & chiasm proximity ▪ Microadenomas <5 mm: MRI q2–3 yrs; may stop if stable ▪ Macroadenomas/near chiasm: MRI @6–12 mo +

Pituitary Society international consensus guideline statement on pituitary incidentalomas. https://t.co/5WOXwvNckd

Adipose tissue thermogenesis in humans is not simply proportional to skin temperature. New research shows greater heat production at 26°C vs 30°C, mainly due to increased shivering, not changes in brown fat activity. Sex differences in shivering seen only at colder temps.

Highly recommend this outstanding free virtual CME on #MASLD/#MASH! The 3rd Annual Mount Sinai MASLD/MASH Center of Excellence Symposium. @MeenaBBansal. 📅 Oct 10, 2025 | 8 AM–4:15 PM ET 🖥️ Virtual Program https://t.co/GtjW4otOnE

Organ-specific imaging biomarkers in obesity care. MRI, CT, PET, & ultrasonography now quantify adiposity, fibrosis, heart & brain changes, and pancreatic dysfunction. Automation & AI enable whole-body MRI segmentation for subcutaneous/visceral fat and muscle, guiding risk

Imaging is important in obesity care but comes with challenges. CT, US, and MRI each face technical barriers, yet AI-enhanced methods, body composition biomarkers, and advanced MRI for MASLD/MASH, pancreas, heart, and joints point to a future where imaging drives precision

It was an honor to share insights about weight loss medications with @prathiksvinod for @firstpost, a leading Indian news channel. https://t.co/acQlhb67uu

CKM health and heart failure prevention: A life course approach integrates risk stratification, metabolic-bariatric surgery, and advanced therapies like GLP-1, GIP, and SGLT2 inhibitors. Early, coordinated management of metabolic, kidney, and cardiac risks is key to reducing

Metabolic and endocrine risk factors are central to heart failure prevention. Addressing obesity, insulin resistance, and metabolic syndrome creates new opportunities to halt heart failure before it starts. https://t.co/hjCLHsGvuS

AACE - MENA Conference 🔍 In-Depth Symposia Spotlight - Obesity in Depth 📅 Saturday, November 22, 2025 🕑 13:45 – 15:15 📍 InterContinental Dubai Festival City | Hall B https://t.co/xyodNJUaIz

A new era in obesity treatment: medications like #semaglutide and #tirzepatide target hunger pathways, offering sustained weight loss of 15–21%. More potent therapies and next-gen biologics, dual and triple agonists, are under development. https://t.co/vDcvZef9wB

Current perspectives from @US_FDA on NITs as alternatives to biopsy in MASH drug development. Elastography, blood tests, and combo tests are key to enhancing trial recruitment and patient experience while maintaining regulatory standards. https://t.co/Xqde4SbgY5